Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04359186 · ClinicalTrials.gov registry record · NA

SCOPE Analytic Treatment Interruption Protocol

A NA study of HIV/AIDS, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT04359186 is a NA study of HIV/AIDS that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04359186, a NA study of HIV/AIDS, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.

Conditions Studied

Interventions

  • OTHER Treatment Interruption Arm

Study Locations (1)

California

  • University of California San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-10-15
Est. Completion 2028-06
Phase NA

What the Registry Record Tells You About NCT04359186

The ClinicalTrials.gov registry entry for NCT04359186 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Treatment Interruption Arm is the first listed.

NCT04359186 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04359186 about?

NCT04359186 is a clinical study titled "SCOPE Analytic Treatment Interruption Protocol". The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy wit...

What is the current status of trial NCT04359186?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2020-10-15. Estimated completion is 2028-06.

What conditions does trial NCT04359186 study?

This clinical trial studies the following conditions: HIV/AIDS.

What interventions are being tested in trial NCT04359186?

The interventions under investigation include: Treatment Interruption Arm (OTHER).

Who is sponsoring clinical trial NCT04359186?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04359186 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.